These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 38020744)
1. A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection. van Vugt LK; van der Zwan M; Clahsen-van Groningen MC; van Agteren M; Hullegie-Peelen DM; De Winter BCM; Reinders MEJ; Miranda Afonso P; Hesselink DA Transpl Int; 2023; 36():11834. PubMed ID: 38020744 [TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients. Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773 [TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab induction in deceased donor kidney transplantation. Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection. van der Zwan M; Clahsen-Van Groningen MC; van den Hoogen MWF; Kho MML; Roodnat JI; Mauff KAL; Roelen DL; van Agteren M; Baan CC; Hesselink DA Front Immunol; 2020; 11():1332. PubMed ID: 32719676 [TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab Induction Is Associated With Equalization of Graft Outcomes Between Elderly and Nonelderly Kidney Transplant Recipients: A Single-Center Report. DeLeonibus A; Mitro G; Brooks J; Rees M; Ortiz J Exp Clin Transplant; 2020 Jun; 18(3):284-291. PubMed ID: 31050614 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up. Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093 [TBL] [Abstract][Full Text] [Related]
13. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis. Sampaio MS; Chopra B; Sureshkumar KK Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563 [TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Lü TM; Yang SL; Wu WZ; Tan JM Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554 [TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom. Chukwu CA; Spiers HVM; Middleton R; Kalra PA; Asderakis A; Rao A; Augustine T Transplant Rev (Orlando); 2022 Apr; 36(2):100686. PubMed ID: 35151219 [TBL] [Abstract][Full Text] [Related]
16. Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study. Erez DL; Pizzo H; Rodig N; Richardson T; Somers M; Pediatr Nephrol; 2023 Oct; 38(10):3455-3464. PubMed ID: 37154962 [TBL] [Abstract][Full Text] [Related]
17. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin. Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622 [TBL] [Abstract][Full Text] [Related]
18. Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction. Weissenbacher A; Hautz T; Kimelman M; Oberhuber R; Ulmer H; Bösmüller C; Maglione M; Schneeberger S J Immunol Res; 2015; 2015():985460. PubMed ID: 26171403 [TBL] [Abstract][Full Text] [Related]
19. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal. Saull HE; Enderby CY; Gonwa TA; Wadei HM Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849 [TBL] [Abstract][Full Text] [Related]
20. Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients. Niu Q; Mendoza Rojas A; Dieterich M; Roelen DL; Clahsen-van Groningen MC; Wang L; van Gelder T; Hesselink DA; van Besouw NM; Baan CC Front Immunol; 2020; 11():1972. PubMed ID: 32983131 [No Abstract] [Full Text] [Related] [Next] [New Search]